156 related articles for article (PubMed ID: 36683866)
21. Long-Term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD.
Iwadare T; Kimura T; Kunimoto H; Okumura T; Wakabayashi SI; Kobayashi H; Yamashita Y; Sugiura A; Tanaka N; Umemura T
Front Endocrinol (Lausanne); 2024; 15():1329294. PubMed ID: 38828415
[TBL] [Abstract][Full Text] [Related]
22. Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up.
Ikeda S; Sugihara T; Kihara T; Matsuki Y; Nagahara T; Takata T; Kitao S; Okura T; Yamamoto K; Isomoto H
Diagnostics (Basel); 2021 Dec; 11(12):. PubMed ID: 34943553
[TBL] [Abstract][Full Text] [Related]
23. Stratification by Non-invasive Biomarkers of Non-alcoholic Fatty Liver Disease in Children.
Kwon Y; Kim ES; Choe YH; Kim MJ
Front Pediatr; 2022; 10():846273. PubMed ID: 35444966
[TBL] [Abstract][Full Text] [Related]
24. Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study.
Hatanaka T; Kakizaki S; Saito N; Nakano Y; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Kashiwabara K; Yoshinaga T; Tojima H; Naganuma A; Uraoka T
Intern Med; 2021 Jul; 60(14):2167-2174. PubMed ID: 33612679
[TBL] [Abstract][Full Text] [Related]
25. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis.
Honda Y; Kessoku T; Ogawa Y; Tomeno W; Imajo K; Fujita K; Yoneda M; Takizawa T; Saito S; Nagashima Y; Nakajima A
Sci Rep; 2017 Feb; 7():42477. PubMed ID: 28195199
[TBL] [Abstract][Full Text] [Related]
26. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease?
Kumar R; Rastogi A; Sharma MK; Bhatia V; Garg H; Bihari C; Sarin SK
Indian J Endocrinol Metab; 2013 Jul; 17(4):665-71. PubMed ID: 23961483
[TBL] [Abstract][Full Text] [Related]
27. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
28. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
29. Different predictors of steatosis and fibrosis severity among lean, overweight and obese patients with nonalcoholic fatty liver disease.
Shao C; Ye J; Li F; Feng S; Wang W; Zhong B
Dig Liver Dis; 2019 Oct; 51(10):1392-1399. PubMed ID: 30928418
[TBL] [Abstract][Full Text] [Related]
30. Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients.
Denkmayr L; Feldman A; Stechemesser L; Eder SK; Zandanell S; Schranz M; Strasser M; Huber-Schönauer U; Buch S; Hampe J; Paulweber B; Lackner C; Haufe H; Sotlar K; Datz C; Aigner E
J Clin Med; 2018 Dec; 7(12):. PubMed ID: 30562976
[TBL] [Abstract][Full Text] [Related]
31. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non-obese and lean population of living liver donors: The impact of uric acid.
Eshraghian A; Nikeghbalian S; Geramizadeh B; Kazemi K; Shamsaeefar A; Malek-Hosseini SA
Clin Res Hepatol Gastroenterol; 2020 Sep; 44(4):572-578. PubMed ID: 31611031
[TBL] [Abstract][Full Text] [Related]
32. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
Akyuz U; Yesil A; Yilmaz Y
Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
[TBL] [Abstract][Full Text] [Related]
33. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610
[TBL] [Abstract][Full Text] [Related]
34. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population.
Feng RN; Du SS; Wang C; Li YC; Liu LY; Guo FC; Sun CH
World J Gastroenterol; 2014 Dec; 20(47):17932-40. PubMed ID: 25548491
[TBL] [Abstract][Full Text] [Related]
35. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
[TBL] [Abstract][Full Text] [Related]
36. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
37. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of switching to pemafibrate from bezafibrate in patients with chronic liver disease.
Tamai H; Okamura J
Hepatol Res; 2023 Mar; 53(3):258-266. PubMed ID: 36378065
[TBL] [Abstract][Full Text] [Related]
39. Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.
Kiyoaki I; Sumida Y; Nakade Y; Okumura A; Nishimura S; Ibusuki M; Kitano R; Sakamoto K; Kimoto S; Inoue T; Kobayashi Y; Fukuzawa Y; Yoneda M
PLoS One; 2022; 17(11):e0277380. PubMed ID: 36355761
[TBL] [Abstract][Full Text] [Related]
40. Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population.
Li H; Chen Y; Tian X; Hong Y; Chen C; Sharokh NK; Jiao J
Arch Med Sci Atheroscler Dis; 2019; 4():e191-e195. PubMed ID: 31538123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
